Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07594548 | Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | not yet recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07590583 | Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial | not yet recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07493044 | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT05353439 | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT06747390 | Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery(856397) | recruiting | Phase 1 | 30 | Ryan CareyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07217028 | Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 60 | Eben RosenthalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | recruiting | Phase 1 | 18 | Thomas Jefferson UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT07279116 | ABY-029 Head & Neck Trial | not yet recruiting | Phase 1 | 24 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT04403620 | HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 59 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04620603 | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | active not recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | recruiting | Phase 1 / Phase 2 | 45 | Sichuan UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07040072 | Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC(LONG'E) | recruiting | Phase 1 | 10 | Beijing Tongren HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02088645 | 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.(Lumed) | active not recruiting | Phase 1 | 24 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03465618 | A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07249879 | This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. | recruiting | Phase 1 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 36 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | recruiting | Phase 1 | 15 | University of HawaiiOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02589522 | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06477523 | Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC | active not recruiting | Phase 1 / Phase 2 | 57 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07072234 | Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2026source: clinicaltrials